Agency liposomal of therapy on morfo-functional status of cardiovascular system at rheumatic mitral heart diseases for patients with accompanying COPD
Agency new cardio protective liposomal materials on a mofro-functional status of cardiovascular system for patients with mitral rheumatic heart diseases is in-process estimated. It is displayed, that add-on of such therapy in the complex of medical measures at a mitral stenosis contributes in reduction of tags of a hypertrophy of the left auricle, and at mitral insufficiency - to reduction of the left departments of heart, a right ventricle and diastolic dysfunction.